XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Oct. 31, 2022
Oct. 31, 2021
Oct. 31, 2022
Oct. 31, 2021
Income Statement [Abstract]        
Oncology services revenue $ 14,281 $ 11,786 $ 28,026 $ 23,039
Costs and operating expenses:        
Cost of oncology services 7,443 5,609 14,495 11,005
Research and development 2,604 2,299 5,491 4,603
Sales and marketing 1,700 1,640 3,392 3,214
General and administrative 2,527 1,975 4,925 4,129
Total costs and operating expenses 14,274 11,523 28,303 22,951
Income (loss) from operations 7 263 (277) 88
Other income (loss) (9) 26 (27) 43
Income (loss) before provision for income taxes (2) 289 (304) 131
Provision for income taxes 14 12 31 26
Net income (loss) $ (16) $ 277 $ (335) $ 105
Net (income) loss per common share outstanding        
Net (income) loss per common share outstanding, basic (in dollars per share) $ (0.00) $ 0.02 $ (0.02) $ 0.01
Net (income) loss per common share outstanding, diluted (in dollars per share) $ (0.00) $ 0.02 $ (0.02) $ 0.01
Weighted average common shares outstanding        
Weighted average common shares outstanding, basic (in shares) 13,528,643 13,428,508 13,521,496 13,145,930
Weighted average common shares outstanding, diluted (in shares) 13,528,643 14,549,136 13,521,496 14,213,450
Revenue, Product and Service [Extensible List] Service [Member] Service [Member] Service [Member] Service [Member]
Cost, Product and Service [Extensible List] Service [Member] Service [Member] Service [Member] Service [Member]